secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001171843-24-002861
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose posts Q1 net loss of $9.6M; advances TUS+VEN+HMA triplet to clinical site activation
--------------------------------------------------------------------------------

- Net loss of $9.6M ($0.73/share) vs $13.7M ($2.22) a year ago; cash $9.3M expected to fund through August 2024.
- Tuspetinib triplet (TUS+VEN+HMA) protocol for ND AML submitted to FDA; clinical sites being activated; initial data expected Q4 2024.
- Stockholders' equity positive $137k as of March 31, but Nasdaq equity deficiency notice remains; compliance plan due May 17, 2024.
- EHA 2024 poster accepted for TUS monotherapy and TUS+VEN doublet data in R/R AML; preclinical data showing TUS activity against VEN-resistant AML.
- Nasdaq compliance regained regarding Hanmi warrant issue; second deficiency notice for equity minimum still open.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/0001171843-24-002861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184324002861/f8k_051424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer